<SEC-DOCUMENT>0001171843-24-003502.txt : 20240618
<SEC-HEADER>0001171843-24-003502.hdr.sgml : 20240618
<ACCEPTANCE-DATETIME>20240618163032
ACCESSION NUMBER:		0001171843-24-003502
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240618
FILED AS OF DATE:		20240618
DATE AS OF CHANGE:		20240618

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evaxion Biotech A/S
		CENTRAL INDEX KEY:			0001828253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39950
		FILM NUMBER:		241052289

	BUSINESS ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
		BUSINESS PHONE:		004531262615

	MAIL ADDRESS:	
		STREET 1:		DR NEERGAARDS VEJ 5F
		CITY:			HOERSHOLM
		STATE:			G7
		ZIP:			2970
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_061824.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 12pt/0.05pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; border-top: black 3pt solid; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 1.8pt 0 0; border-top: black 1pt solid; text-align: center">&nbsp;</P>

<P STYLE="font: 14.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 14.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"></P>

<P STYLE="font: 14.5pt Times New Roman, Times, Serif; margin: 0.15in 59.6pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PURSUANT TO
SECTION&nbsp;13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNDER THE SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0.15in 59.6pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>For
the&nbsp;month of June 2024</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0.15in 59.6pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Commission
File Number: 001-39950</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0.15in 59.6pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0.15in 59.6pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Evaxion
Biotech A/S</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 4.5pt 59.6pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Exact
Name of Registrant as Specified in Its Charter)</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 4.5pt 59.6pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Dr.
Neergaards Vej 5f</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DK-2970 Hoersholm</B></FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Denmark</B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address
of principal executive offices)</B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 10%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 6.5pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-size: 10pt">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F
</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;Form&nbsp;40-F
</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></P>

<P STYLE="font: 9pt Calibri, Helvetica, Sans-Serif; margin: 0.1in 59.6pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.75pt 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>INCORPORATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B></B>This report on
Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S&rsquo;s registration statements on Form S-8 (File No.
333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), and Form
F-1 (File No. 333-279153), including any prospectuses forming a part of such registration statements and to be a part thereof from the
date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.75pt 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.75pt 12pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.75pt 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><I>Notice of Extension to Comply with Continued Listing
Rule</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As previously announced, on May 7, 2024, the Nasdaq
Stock Market LLC (&ldquo;Nasdaq&rdquo;) Listing Qualifications Department notified Evaxion Biotech A/S (the &ldquo;Company&rdquo;) that
it no longer complied with Nasdaq Listing Rule 5550(b)(1) (the &ldquo;Rule&rdquo;). Under the Rule, companies listed on Nasdaq must maintain
stockholders&rsquo; equity of at least $2,500,000 (the &ldquo;Stockholders&rsquo; Equity Requirement&rdquo;). The Company&rsquo;s stockholders&rsquo;
equity of $(4,729,000) for the period ended December 31, 2023 was below the Stockholders&rsquo; Equity Requirement for continued listing.
Additionally, the Company did not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules of
market value of listed securities or net income from continuing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 31, 2024, the Company submitted a plan to
the staff at the Nasdaq Listing Qualifications Department (the &ldquo;Staff&rdquo;) to regain compliance with the Stockholders&rsquo;
Equity Requirement (the &ldquo;Compliance Plan&rdquo;), and on June 13, 2024, the Staff notified the Company (the &ldquo;Letter&rdquo;)
that it would be granted an extension until November 4, 2024, to demonstrate compliance with Listing Rule 5550(b)(1) to meet the continued
listing requirements of Nasdaq, conditioned upon the Company evidencing compliance with the Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company intends to regain compliance
with the applicable continued listing requirements of Nasdaq prior to the end of the compliance period set forth in the Letter. The Company
has determined that its deficiency in minimum stockholder&rsquo;s equity was partly a result of the IFRS accounting treatment of its
investor warrants that are treated as a derivative liability, hence reducing equity.&nbsp;The Company has, as announced on May 24, already
amended outstanding investor warrants from the February public offering. The Company also intends to amend remaining outstanding investor
warrants and to take other steps in accordance with its Compliance Plan to ensure compliance with Nasdaq listing rules.&nbsp;However,
until Nasdaq has reached a final determination that the Company has regained compliance with all of the applicable continued listing
requirements, there can be no assurances regarding the continued listing of the Company&rsquo;s common stock on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 59.6pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 59.6pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evaxion
    Biotech A/S</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; padding-right: 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June
    18, 2024</FONT></TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Christian Kanstrup</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christian Kanstrup</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0.75pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0 59.6pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
